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Introduction:  Although  primary  immune  thrombocytopenia  (ITP)  is  rare  in  childhood,  it  is  the
most frequent  cause  of  thrombocytopenia.  There  have  been  attempts  to  establish  risk  factors  to
predict  the  progression  of  the  disease  in  order  to  optimise  its  management,  which  has  changed
in  recent  years  due  to,  among  other  reasons,  specialised  care.
Material  and  methods:  A  retrospective,  observational  and  analytical  study  was  conducted  on
patients diagnosed  with  ITP  over  a  3-year  period  in  a  Paediatric  Haematology  specialist  clinic.
Results:  From  the  epidemiological,  clinical  and  analytical  point  of  view,  the  characteristics  of
this  group  are  similar  to  others.  Most  of  the  patients  (23/31,  74.2  %)  had  ITP  for  less  than
12  months,  with  there  being  no  serious  complications  related  to  the  disease  or  the  treatment
received. It  was  established  that  risk  factors  were  related  to  being  slowly  evolving  (lower  event-
free  survival  (EFS))  with  no  statistical  significance,  female  gender,  age  over  10  years,  leukopenia
absence  of  initial  severe  thrombocytopenia,  and  non-specialised  care.  The  absence  of  a  history
of  infection  was  significantly  related  to  a  lower  EFS.
Conclusions:  The  epidemiological  and  analytical  risk  factors  for  a  slowly  evolving  ITP  are  the
same that  described  in  the  literature.  Patients  treated  before  the  beginning  of  specialised
care  also  had  a  lower  EFS.  These  data  seem  to  support  the  current  recommendation  that  rare
diseases  should  be  managed  in  specialised  units.
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he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).






Factores de  riesgo;
Supervivencia
Trombocitopenia  inmune  primaria:  experiencia  de  una  consulta  especializada  en
Hematología
Resumen
Introducción:  La  trombopenia  inmune  primaria  (PTI)  es  poco  frecuente  en  la  infancia,  pero  es
la causa  más  habitual  de  trombopenia.  Se  han  intentado  establecer  factores  de  riesgo  para
predecir  su  evolución,  con  el  objetivo  de  poder  optimizar  su  manejo,  que  se  ha  modificado  en
los  últimos  años,  debido  entre  otros  factores,  a  una  atención  más  especializada.
Material y  métodos:  Estudio  retrospectivo,  observacional  y  analítico  de  los  pacientes  con  PTI,
en un  periodo  de  3  años,  en  una  consulta  especializada  en  Hematología  Pediátrica.
Resultados: Desde  el  punto  de  vista  epidemiológico,  clínico  y  analítico,  las  características  de
esta  serie  son  similares  a  las  de  otros  grupos.  La  mayoría  de  los  pacientes  (23/31;  74.2  %)  pre-
sentaron  una  PTI  de  duración  menor  de  12  meses,  sin  complicaciones  graves  relacionadas  con  la
enfermedad  ni  con  el  tratamiento.  Se  establecieron  como  factores  de  riesgo  relacionados  con
una  evolución  tórpida  (supervivencia  libre  de  eventos  (SLE)  menor),  sin  alcanzar  la  significación
estadística,  el  sexo  femenino,  la  edad  mayor  de  10  años,  la  leucopenia,  la  ausencia  de  trom-
bopenia  grave  inicial  y  la  atención  no  especializada.  La  ausencia  de  antecedente  de  infección
se  relacionó  significativamente  con  una  SLE  menor.
Conclusiones:  Los  factores  de  riesgo  de  evolución  tórpida  de  PTI  epidemiológicos  y  analíticos
de este  estudio  coinciden  con  los  descritos  en  la  literatura.  Presentaron  una  SLE  menor  los
pacientes  tratados  antes  del  inicio  de  la  atención  especializada.  Estos  datos  parecen  apoyar  la
recomendación  actual  de  que  las  enfermedades  poco  frecuentes,  como  ésta,  se  controlen  en
unidades  especializadas.
© 2020  Publicado  por  Elsevier  España,  S.L.U.  en  nombre  de  Asociación  Española  de  Pediatŕıa.




























Primary  immune  thrombocytopenia  (PIT)  is a  disease  charac-
terised  by  an isolated  decrease  in the platelet  count  to under  100
000/mm3 without  an  identified  trigger.  At  present,  the qualifier
‘‘chronic’’  is applied  starting  from  12 months  post  diagnosis.1,2
It is the  most  common  form of acute  thrombocytopenia  in
healthy  children,  but  it  is not  a frequent  disease.  The  incidence
in  children  aged  less  than 15  years  is estimated  at about  5 cases
per  100 000  inhabitants  per year.3
It is  mainly  characterised  by  haemorrhagic  manifestations  at
3  levels:  the skin,  mucosae  and  internal  organs.  Most  patients
are  asymptomatic  or have  cutaneous/mucosal  manifestations.
Different  clinical  scales  have  been  developed  to objectively
assess  the  intensity  of bleeding,  among  which  one  of the most
widely  used  is the  one  proposed  by the  World  Health  Organiza-
tion  (WHO):  grade  0: no  evidence  of bleeding;  grade  1: minor
bleeding  (petechiae,  ecchymoses,  mucocutaneous  haemorrhage,
retinal  bleeding  without  visual  impairment);  grade  2:  gross  bleed-
ing  (melanotic  stool,  haematemesis,  haematuria,  haemoptysis);
grade  3:  any  bleeding  requiring  red blood  cell (RBC)  transfusion;
grade  4:  retinal  bleeding  with visual  impairment,  central  ner-
vous  system  bleeding.  Only  3  % of  paediatric  patients  develop
clinically  significant  bleeding,  and  the most frequent  manifesta-
tions  in  this  subset  is  epistaxis  and  gastrointestinal  bleeding.3 The
intensity  of  bleeding  appears  to be  associated  with  the  severity
of  thrombocytopenia,  although  there  is no exact  or direct  corre-
lation  between  these  2 variables.  The  most  severe  complication
is  intracranial  haemorrhage  (ICH),  with a frequency  that ranges
from  0.1  % to 0.6 %. To  date,  no  clear  predictor  of ICH  has  been





Primary  immune  thrombocytopenia  is a  diagnosis  of  exclusion.
he  key elements  for  diagnosis  of PIT  are  an unremarkable  per-
onal  and  family history  and  a normal  physical  examination (with
he  exception  of bleeding  manifestations)  associated  with the
resence  of isolated  thrombocytopenia.  Most  patients  have a  his-
ory  of viral  infection  (60  % of  upper respiratory  tract  infection
nd  exanthema),  vaccination  (most frequently  the  measles-
umps-rubella  [MMR] vaccine)  or  bacterial  infection  in  the  weeks
receding  onset.3,4 Any abnormalities  in the blood  count  other
han  isolated  thrombocytopenia  and/or  abnormalities  in the
hysical  examination  (dysmorphic  features,  visceromegaly  etc)  or
n  the  clinical  history  (recurrent  infection,  fever,  medication,  etc)
hould  at  least prompt  reconsideration  of the PIT  diagnosis.7,8
Primary  immune  thrombocytopenia  is  a benign and self-
imiting  disease.  Different  registers  and  published  studies  show
emission  in  60  % of cases  within  6  months  of diagnosis,  indepen-
ently  of the treatment  given.3,9 The  identification  of  predictors
f  remission  has  proven  challenging.  There  is  evidence  of  an
ssociation  between  a  favourable  outcome  and  the  following
ariables:  male  sex,  age  less  than  10  years,  abrupt  onset,  his-
ory  of infection  preceding  onset  and  a  very low  platelet  count
<5000/mm3).10--13 The presence  of leukopenia  also  seems  to be
ssociated  with an increased  risk  of persistent  or  chronic  PIT.14
The  drugs  used  most frequently  in  the management  of  PIT  have
een  corticosteroids  and  intravenous  immunoglobulin  (IVIG).15--18
istorically,  treatment  was  prescribed  with  the aim of  increasing
he  platelet  counts.  In  light of the  rarity  of significant  bleeding,
he  lack  of evidence  demonstrating  that pharmacotherapy  pre-
ents  severe  bleeding  and  the  economic  cost  and known toxicity
f  the  different  drugs  available,  the approach  to the manage-
ent  of PIT is more  conservative,  and  observation  is currently
ecommended  for  asymptomatic  or mildly  symptomatic  children.
18  C.  Rodríguez-Vigil  Iturrate  et  al.
Table  1  Laboratory  values  at  diagnosis.
n  Minimum  Maximum  Mean  Median  Standard  deviation
Total  WBC/mm3 29  4900  15  700  9891  10  100  3051
Haemoglobin  (g/dL)  29  7.6  14.3  12.5  13  1.4
Platelets/mm3 31  457  47  000  11  079  9000  9348

























































































WBC, white blood cell.
hen  pharmacotherapy  is used, since  there  is no  evidence  of the
uperiority  of  any  of  the  available  drugs,  it  is recommended  that
he  advantages  and  disadvantages  of each  are  considered  and
iscussed  with  the  patients  and  their  families  to establish  an indi-
idualised  treatment  plan.3,9,19 This  shift  in  the  approach  to the
anagement  of  PIT has been reflected  in  the  different  protocols
nd  guidelines  published  in  recent  years,  including  the  protocol
f  the Sociedad  Española  de Hematología  y  Oncología  Pediátri-
as  (Spanish  Society  of  Paediatric  Haematology  and Oncology,
EHOP).19--21
In  2013,  a  specialised  clinic  in  paediatric  haematology  opened
ts  doors  in  the  Hospital  Infantil  Miguel  Servet  of Zaragoza,  Spain,
o  carry out  the  diagnosis,  treatment  and  follow-up  of patients
ith  diagnosis  of noncancerous  blood  disorders,  including  PIT.
ntil  then,  cases  of PIT in  this  children’s  hospital  were  man-
ged  by  various  providers  that  were not  specialists  in  paediatric
aematology.  Once  the  clinic  opened,  it routinely  applied  the
rotocols  endorsed  by  paediatric  haematology  societies.20
The  aim  of our study  was  to establish  the  clinical  and  lab-
ratory  characteristics  and  the outcomes  of patients  with  PIT
valuated  in  this specialty  clinic  and  to assess  the  risk  factors
hat  may be  associated  with a protracted  course.
ample and methods
e conducted  a retrospective,  observational  and  analytical  study
y  reviewing  the  health  records  of  patients  with  a  diagnosis  of PIT
anaged  between  January  2013  and October  2016  in the  paedi-
tric  haematology  clinic  of the Hospital  Infantil  Miguel  Servet  in
aragoza.
We  included  patients  aged  less  than  15 years  with a diagnosis
f  PIT managed  in the  clinic  during  the  period  under  study regard-
ess  of the date of the  initial  diagnosis.  We excluded  patients  with
nsufficient  follow-up  data.
We applied  the diagnostic  criteria,  definitions  for  assessment
f  response  to treatment  and  the  treatments  specified  in the
urrent  protocol  of  the  SEHOP  for  the management  of PIT.20
We  collected  data  on demographic  and  epidemiologic  varia-
les,  laboratory  tests,  treatment,  response  to treatment,
ollow-up  and  outcomes.  The  data  collection  process  adhered  to
he  current  legislation  on the  protection  of  personal  data.
We compared  variables  by means  of the  2 and  Student  t
ests.  To  assess  the  association  between  variables,  we  performed
inary  logistic  regression  analyses  where  the  dependent  variable
as  the  type of PIT based  on  the  duration  of illness  (less  than
r  greater  than  12 months).  We  also performed  a  survival  anal-
sis,  defining  event-free  survival  (EFS)  as  the  time  elapsed  (in
onths)  from  diagnosis  to whichever  of the  following  occurred
rst:  low platelet  count of less  than  30 000/mm3, death, dis-
harge  or end  of  the  study  (October  31,  2016).  We  plotted  survival
urves  using the  Kaplan-Meier  method.  We  compared  the  differ-
nce  in  EFS based  on  different  clinical,  diagnostic  and  treatment





ion,  platelet  and  white  blood  cell counts,  management  in the
pecialty  clinic  or prior  to the opening  of the  speciality  clinic)
ith  the  Kaplan-Meier  method  and  the long-rank  test.  We  defined
tatistical  significance  as  a  p-value  or B  value  of  less  than 0.05.
he  statistical  analysis  was performed  with  the software  IBM  SPSS
ersion  24.
esults
etween  January  2013  and  October  2016,  509  patients  were
ssessed  in  the paediatric  haematology  clinic  for  some  form  of
oncancerous  blood  disorders.  Of  this  total,  44 (8.6 %) had  a
iagnosis  of thrombocytopenia,  and  31 (70  % of  patients  with
hrombocytopenia)  a  diagnosis  of PIT.  Based on  this finding and
he  census  data  of the  Instituto  Aragonés  de Estadística  (Institute
f  Statistics  of Aragon),  we  calculated  an incidence  in  children
ged  less  than 15  years  of 2.6  cases  per  100 000  inhabitants  per
ear.
The  distribution  of  patients  by  sex was  18  male  and 13  female
1.3:1  ratio).  The  mean  age  at  diagnosis  was 4.5  years,  with
 median  of 4  years  and a  range  of 0--13  years.  Most patients
27/31)  were  aged  less  than 10  years  at the  time of  diagno-
is.
When  it came  to the  clinical  manifestations,  2  patients  (6.5
)  did  not  have  any  overt  bleeding,  and  the diagnosis  was made
hen  blood  tests  were  done  for  other  reasons.  In the remain-
ng  29 patients  there  were  bleeding  manifestations:  cutaneous  in
ll,  as well  as mucosal  in  12  (38.7  %), and  epistaxis  was the  most
requent  form  of bleeding  (10/12;  83  %),  followed  by  gastroin-
estinal  bleeding.  We did  not  find  a recent  history  of  vaccination
n  any of the  patients,  but  found  a history  of  recent  infection in
3  (41.9  %).
The mean  platelet  count  at  diagnosis  was  11  000/mm3, and
he  median  was 9000/mm3.  In  addition,  83.8  % of  the  patients
ad  platelet  counts  of  less  than 20  000/mm3 at  diagnosis  and
3  %  had very  severe  thrombocytopenia  (< 5000  platelets/mm3).
he  platelet  count  at admission  did  not exceed  50  000/mm3 in
ny  case.  The initial  haemoglobin  concentration  was abnormal
n  2  patients,  who  underwent  bone  marrow analysis,  confirming
he  peripheral  mechanism  of the  disease.  Six patients  (19.4  %)
ad  white  blood  cell (WBC) counts  of  less  than  6000  cells/mm3
t  diagnosis,  and  most  of them (66  %) progressed  to chronic  PIT
Table  1).
Of the  31 patients,  3 (9.7  %)  did  not  receive  any  pharmacother-
py  during  the  follow-up,  and  the thrombopenia  resolved  within
 months  in all. Thirteen  (46.8  %) received  1 treatment,  most
requently  prednisone  (8 patients),  followed  by  IVIG  (5  patients).
welve  patients  required  2  treatments,  either  due to poor  clini-
al  response  and/or  poor improvement  of  laboratory  parameters,
nd  treatments  other  than  prednisone  or IVIG  were  used in 3
atients  (dexamethasone,  rituximab,  thrombopoietin  receptor
gonists,  splenectomy).  One patient  had  haemodynamically  sig-
ificant  epistaxis  requiring  transfusion.  None  of  the patients  died
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Table  2  Clinical,  laboratory  and  treatment  characteristics  of  patients  by  duration  of  disease.
All  patients  (n  =  31)  ≤  12  months  (n  =  23)  >  12  months  (n  =  8)
Sex,  n  (%)
Male 18  (58.1)  15  (65.2)  3  (37.5)
Female  13  (41.9)  8  (34.8)  5  (62.5)
Age  in  years
Mean (range)  4.5  (0--13)  3.7  (0--13)  7  (4--11)
<10  years,  n  (%)  27  (87.1)  22  (95.7)  5  (62.5)
≥10  years,  n  (%)  4  (12.9)  1  (4.3)  3  (32.5)
Cutaneous  bleeding,  n  (%)
No 2  (6.5) 2  (8.7) 0
Yes 29 (93.5) 21  (91.3) 8  (100)
Mucosal  bleeding,  n  (%)
No 19  (61.3)  14  (60.9)  5  (62.5)
Yes  12  (38.7)  9  (39.1)  3  (37.5)
Previous  infection,  n  (%)
No 18  (58.1)  10  (43.5)  8  (100)
Yes  13  (41.9)  13  (56.5)  0
Platelet  count  in  sample
Mean/mm3 11  079 9889 14  500
Median/mm3 9000  9000  9000
Range/mm3 457--47  000 457--27  000 5000--47  000
Platelet count,  n  (%)
<10 000/mm3 16  (51.6)  12  (52.2)  4  (50)
≥10  000/mm3 15  (48.4)  11  (47.8)  4  (50)
Platelet  count,  n  (%)
<5000/mm3 4  (12.9)  4  (17.4)  0
≥5000/mm3 27  (87.1)  19  (89.6)  8  (100)
WBC  count  in  sample
Mean 9891  10  560  7323
Median  10  100  10  700  7045
Range  4900--15  700  4900--15  700  4900--11  150
WBC count,  n  (%)
<6000/mm3 6  (19.4)  2  (8.7)  4  (50)
≥6000/mm3 25  (80.6)  21  (91.3)  4  (50)
Treatment,  n  (%)
No 3  (9.7)  3  (13)  0
Yes 28  (90.3)  20  (87)  8  (100)
Type  of  treatment,  n  (%)
IVIG alone  5  (16.1)  5  (21.7)  0
Prednisone  alone  8  (25.8)  5  (21.7)  3  (37.5)
IVIG  +  prednisone  12  (38.7)  10  (43.5)  2  (25)
IVIG  +  prednisone  +  other  3  (9.7)  0  3  (37.5)





IVIG, intravenous immunoglobulin; WBC, white blood cell.
or  had life-threatening  haemorrhage  in the period  under  study.
Using  the  bleeding  scale  of the  WHO,  most  patients  (28/31;  90.3
%)  had  grade  1--2  bleeding.  There  were  2  cases  of grade  0, 1 case
of  grade  3 and  no  cases  of grade  4  bleeding.Twenty-nine patients  (93.5  %) reached  platelet  counts  greater
than  100  000/mm3 after  a mean  of 150 days and  a  median  of 65
days.  Eleven  (35.4  %)  experienced  a decrease  of platelets  to less




rom diagnosis  of 87  days  and  a median  of 30 days.  All  patients
hat  experienced  a decrease  in  the platelet  count received  at
east  1  treatment  at  some  point:  3  patients  prednisone  alone,  4
rednisone  and  IVIG and  4 at  least 3 immunomodulating  agents.In most  of the sample, PIT resolved  within  12  months  of  diag-
osis  (23/31;  74.2  %), while  8  patients  (25.8  %) eventually  met
he  criteria  for  chronic  PIT.  In  the group  that  developed  chronic
IT,  there  was a predominance  of female  patients,  the mean  age
20  C.  Rodríguez-Vigil  Iturrate  et  al.
Fig.  1  Kaplan-Meier  curve  of  the  event-free  survival  (EFS)  based  on  the  history  of  recent  infection  (P  =  .001).
PARCHEOS:  cambiar  las  comas  en  los  decimales  a  puntos  en  el  eje  vertical.
Cumulative survival








lue: no  infection
reen: infectionas greater compared  to the  total  sample,  the  mean platelet
ount  at  diagnosis  was  higher,  the  mean  WBC  count  at diagnosis
as  lower,  and there  was no history  of recent  infection.  Com-





Table  4  Event-free  survival  based  on  demographic,  clinical  and  l
Variable  Patients  (n)  
Sex  30  
Male  17  
Female 13  
Age 30  
<10  years  26  
≥10 years  3  
Mucosal bleeding  30  
No  18  
Yes 12  
Previous infection  30  
No  17  
Yes 13  
Platelet count 30  
<  5000/mm3 4  
≥ 5000/mm3 26  
WBC count  30  
<6000/mm3 6  
≥6000/mm3 24  
Management period  30  
Before  opening  of  specialty  clinic  20  
Specialty clinic  10  
EFS, event-free survival; WBC, white blood cell.
The p-values correspond to the log-rank test.2 months’  duration,  we  found that  development  of  chronic  PIT
as  significantly  associated  with greater  age  at diagnosis,  the
resence  of leukopenia  and  the  absence  of  previous  infection.
e  did  not  find  a statistically  significant  association  with  the
aboratory  variables  and  management  period.
Events  (n)  EFS  (%)  P
11
5  70.  6  .37
6  56.8
11
8  69.2  .056
3  25
11
7  61.1  .95
4  66.7
11
11  35  <.05
0  100
11
0  100  .16
11  57.7
11
4  33.3  .06
7  70.8
11
10  50  .06
1  90
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Fig.  2  Kaplan-Meier  curve  of  the  event-free  survival  (EFS)  based  on  age  (P  =  .056).
PARCHEOS: cambiar  las  comas  en  los  decimales  a  puntos  en  el  eje  vertical.
Cumulative survival
Months elapsed  to  event
Survival curves
Blue: <10  years
Green: ≥10  years
Table  3  Variables  with  a  statistically  significant  association
with  chronic  primary  immune  thrombocytopenia  (duration  >
12  months).
≤12  months
(n =  23)
>12 months
(n =  8)
P
Age  in  years
Mean 3.70  7  .01
<10  years  22  5  .01
≥10  years  1  3
Total  WBC  count
Mean 10  560  7323  .01
<  6000/mm3 2  4  .01
≥  6000/mm3 21  4
Previous  infection































Yes  13  0
WBC, white blood cell.
platelet  count,  the  presence  of mucosal  bleeding  or the  treat-
ment  received  (Tables  2  and  3).
As for the type  of  care  received  by  patients  with PIT, we found
that  in  13  cases  the  diagnosis  was  made  before  the  haematol-
ogy  clinic  opened,  while  the  remaining  18  received  the  diagnosis
when  the  clinic  was  already  active.
The binary  logistic  regression  analysis  in  which  the type of PIT
(acute/persistent  or  chronic)  was  the dependent  variable  did  not
find  significant  associations  with  any  of the independent  varia-
bles:  sex,  age,  WBC  and platelet  counts  at  diagnosis,  presence  of
mucosal  bleeding  or treatment  received.We compared  the EFS based  on  different  epidemiological,
clinical  and  treatment  factors  and  found  lower  values  (although
the  differences  were  not  statistically  significant)  in  female




ithout evidence  of  mucosal  bleeding  (P  =  .95),  with platelet
ounts  greater  than  5000/mm3 (P = .16), with  a low  WBC count of
ess  than  6000/mm3 (P = .06),  and  treated  before  the  specialised
aematology  clinic  opened  (P = .06).  The  EFS  was  significantly
ower  (P = .001)  in  patients  without  a previous  history  of  infection
Table  4 and  Figs.  1--4).
Of the 31  patients  under  study,  19 (61.3  %)  were dis-
harged  from  the  clinic  after  at  least  1  year  of  follow-up
ast  the  resolution  of thrombocytopenia.  Twelve  patients  con-
inued  in  follow-up  by the  paediatric  haematology  clinic
ue  to either  chronic  disease  or because  a year  of  follow-
p  had not been  completed  at the  end  of  the  study
eriod.
iscussion
he  epidemiological  data obtained  in  our  study  were  consistent
ith  the previous  literature  and  the  data  collected  in  various
egisters  as pertains  the age  and  sex distribution  of  cases  of  PIT,
ith  the highest  proportion  corresponding  to male  patients  aged
--4  years.3,5 The  estimated  incidence  rate based  on  our  findings
f  2.6  cases  per 100  000  paediatric  patients  per  year was  lower
han  the 5 cases  per 100  000  per year  reported  in  most previous
tudies.3,5 This lower  estimate  may be  attributed  to  several  fac-
ors:  first, that  not  all cases  of PIT in Aragon  were  managed  in
he  hospital  where  we conducted  the  study,  and also that in our
ase  series,  most  patients  had  severe  thrombocytopenia  (mean
latelet  count  of 11  000/mm3, maximum  count  of  47  000/mm3),
nd  that the study  did  not include  patients  with mild  thrombo-
ytopenia  that may  have  met the diagnostic  criteria  for  PIT.  Had
e  included  these  patients  with milder  manifestations,  the inci-
ence  in our  study  would  probably  have  been  closer  to the  one
eported  by other  authors.3,5The  frequency  of  clinically  significant  bleeding  manifesta-
ions  (3  %)  was  consistent  with the  literature,  and the frequency
f  severe  bleeding  has  even lower  than  described  in previous
tudies.3,6,9 There  were  no  cases  of life-threatening  bleeding  dur-
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Fig.  3  Kaplan-Meier  curve  of  the  event-free  survival  (EFS)  based  on  the  white  blood  cell  count  (P  =  .06).
PARCHEOS:  cambiar  las  comas  en  los  decimales  a  puntos  en  el  eje  vertical.
Cumulative survival




Fig.  4  Kaplan-Meier  curve  of  the  event-free  survival  (EFS)  based  on  the  management  period  (P  =  .06).
PARCHEOS: cambiar  las  comas  en  los  decimales  a  puntos  en  el  eje  vertical.
Cumulative survival




















lue: before  specialty  clinic  opened
reen:  after  specialty  clinic  opened
ng the  follow-up.  Two  children  developed  anaemia  in association
ith  the bleeding  episodes,  of who  only  1  required  transfusion
f  blood  products.  These  findings  support  the  notion  that  PIT  is a
enign  disease  in  children  that  is rarely  associated  with  significant
orbidity  or  mortality.
Primary immune  thrombocytopenia  is  frequently  a  self-
imiting  disease  lasting  a few  weeks  or months,  but  in
3,13,14pproximately  25%--30% of cases  it  becomes  chronic. In  our
tudy,  most  samples  achieved  normal  platelet  counts  in  less  than
 months,  and  more  than  two  thirds  of the sample  had a disease




We  did  not  find  differences  based  on  the  treatment  received.
he  most salient  finding  was  that  the  3  patients that  did  not
eceive  any treatment  recovered  spontaneously  in  less  than  6
onths.  The  interpretation  of  these  findings  is limited  by the
mall  sample  size,  but  they  seem  to corroborate  that the  out-
ome  of PIT (resolution  versus  chronic  disease)  does  not  depend
n  the treatment  given.3,10The  identification  of factors  that  may  influence  the  outcome
f  PIT  has  become  a  key  objective  in the  research  devoted  to this
isease,9--14 as clinicians  facing  a  newly  diagnosed  case  cannot













414.e1--414.e8.Primary  immune  thrombocytopenia:  Experience  of  a  special
or  that will  become  a  chronic  ailment,  a difference  that  has  a
significant  impact  on  the  management  and  the  environment  of
the  patient.
In the  sample  under  study,  patients  with  chronic  PIT were
more  frequently  female,  had  a higher  mean age  and  presented
with  nonsevere  thrombocytopenia  and  leukopenia  and  did  not
report  recent  infection  in  the  history  taking  at  the time  of diag-
nosis.  We found  a statistically  significant  association  of chronic
PIT  with older age,  the presence  of leukopenia  and  the absence
of  recent  infection.
The regression  analysis  did  not  yield  statistically  significant
results,  probably  due  to the  small  sample  size,  but  the  survival
analysis  confirmed  the  absence  of a history  of recent  infection
as  a statistically  significant  risk  factor  for  recurrence.  A  possible
explanation  is  that  in  case  there  is  a  clear infectious  trigger  of the
autoimmune  process,  the  thrombocytopenia  would  exhibit  the
expected,  classic  course,  self-limiting  and  benign.  The  absence  of
such  an  infectious  trigger  could  suggest  that  the pathophysiologi-
cal  process  underlying  the  immune  dysregulation  is  multifactorial
and  more  complex,  with  a greater  likelihood  of development
of  chronic  disease.  Other  factors  that were  associated  with  a
lower  EFS,  with results  that  were  not  statistically  significant  but
neared  the significance  threshold,  were  older  age,  the  presence
of  leukopenia  and  management  in  a setting  other  than  the spe-
cialised  haematology  clinic.
Conclusions
The  epidemiological  and outcome  findings  in  our  sample  were
consistent  with  previous  data:  most  patients  were  male,  of
preschool  age,  had a history  of  recent  infection  and most  com-
monly  had bleeding  manifestations  at  the  skin  level,  severe
thrombocytopenia  at  diagnosis  and a favourable  outcome  with
resolution  of  PIT in  less  than  12 months.
Patients who  are  female,  school-aged  or older,  without  evi-
dence  of related  previous  infection,  without  signs  of mucosal
bleeding  or with nonsevere  thrombocytopenia  or leukopenia  at
diagnosis  seem  to be  at  higher  risk  of  protracted  and  recurrent
disease  with  a tendency  toward  chronic  PIT.  Given  the  low  preva-
lence  of this disease,  performance  of  a  prospective  multicentre
study  with  a  larger  sample  would  be  useful  to  corroborate  these
findings  with  greater  accuracy  and  statistical  significance.
In our  sample,  patient  outcomes  improved  once the  spe-
cialised  paediatric  haematology  clinic  was  established.  Based on
our  findings,  albeit  taking  into  consideration  the  limitations  of our
study,  it seems  reasonable  to recommend  that  relatively  infre-
quent  diseases,  such  as  PIT,  be  managed  in specialised  units  with
the  aim  of  minimising  heterogeneity  in  clinical  management  and
offer  the  most appropriate  treatment  available  based  on  up-to-
date  and high-quality  scientific  evidence.
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